{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:13:41Z","timestamp":1792700021725,"version":"4.5.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.clim.2020.108397","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T20:15:51Z","timestamp":1585340151000},"page":"108397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"special_numbering":"C","title":["Comorbidities associated with psoriatic arthritis: Review and update"],"prefix":"10.1016","volume":"214","author":[{"given":"Lourdes M.","family":"Perez-Chada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2020.108397_bb0005","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3899\/jrheum.121500","article-title":"Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis","volume":"40","author":"Husted","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0010","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3899\/jrheum.110893","article-title":"Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia","volume":"39","author":"Marchesoni","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/annrheumdis-2017-211996","article-title":"Validation of the psoriatic arthritis impact of disease (PsAID) questionnaire and its potential as a single-item outcome measure in clinical practice","volume":"77","author":"Holland","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special article: 2018 American college of rheumatology\/National Psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108397_bb0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/key241","article-title":"Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register","volume":"58","author":"Fagerli","year":"2019","journal-title":"Rheumatol. (Oxford, England)"},{"key":"10.1016\/j.clim.2020.108397_bb0030","first-page":"S62","article-title":"Mortality in psoriatic arthritis","volume":"26","author":"Gladman","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0035","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/art.1780401021","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death","volume":"40","author":"Wong","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108397_bb0040","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1002\/art.22800","article-title":"Improved survival in psoriatic arthritis with calendar time","volume":"56","author":"Ali","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108397_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/annrheumdis-2012-202424","article-title":"Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study","volume":"73","author":"Ogdie","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0050","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.3899\/jrheum.100034","article-title":"Mortality in psoriatic arthritis - a single-center study from the UK","volume":"37","author":"Buckley","year":"2010","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108397_bb0060","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"Jama"},{"key":"10.1016\/j.clim.2020.108397_bb0065","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/bjd.12490","article-title":"Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis","volume":"169","author":"Miller","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2020.108397_bb0070","doi-asserted-by":"crossref","first-page":"714321","DOI":"10.1155\/2012\/714321","article-title":"Cardiovascular risk in patients with psoriatic arthritis","volume":"2012","author":"Zhu","year":"2012","journal-title":"Int. J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0075","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/annrheumdis-2015-207980","article-title":"Incidence and predictors for cardiovascular events in patients with psoriatic arthritis","volume":"75","author":"Eder","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0080","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.clim.2020.108397_bb0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.semarthrit.2008.06.001","article-title":"Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease","volume":"39","author":"Gonzalez-Gay","year":"2009","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108397_bb0090","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3899\/jrheum.101124","article-title":"Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting","volume":"38","author":"Boehncke","year":"2011","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0095","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/acr.22144","article-title":"Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis","volume":"66","author":"Lin","year":"2014","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108397_bb0100","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/annrheumdis-2012-201497","article-title":"The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone","volume":"72","author":"Eder","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0105","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/acr.20627","article-title":"Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis","volume":"63","author":"Husted","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108397_bb0110","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1468-3083.2011.04071.x","article-title":"Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a population-based cohort study","volume":"26","author":"Maradit-Kremers","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.clim.2020.108397_bb0115","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.117.030484","article-title":"Inflammation and atherosclerosis: the end of a controversy","volume":"136","author":"Hansson","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.clim.2020.108397_bb0120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/138161282004140213123852","article-title":"Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review","volume":"20","author":"Brezinski","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.clim.2020.108397_bb0125","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jaad.2018.02.040","article-title":"Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis","volume":"79","author":"Lockshin","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2020.108397_bb0130","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.clim.2020.108397_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2011.03.028","article-title":"Attributable risk estimate of severe psoriasis on major cardiovascular events","volume":"124","author":"Mehta","year":"2011","journal-title":"Am. J. Med."},{"key":"10.1016\/j.clim.2020.108397_bb0140","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jaad.2012.05.016","article-title":"The impact of psoriasis on 10-year Framingham risk","volume":"67","author":"Mehta","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2020.108397_bb0145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","article-title":"Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review","volume":"72","author":"Jamnitski","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.clim.2020.108397_bb0155","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamacardio.2019.2589","article-title":"Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index","volume":"4","author":"Elnabawi","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.clim.2020.108397_bb0160","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of Secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.clim.2020.108397_bb0165","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circulation Cardiovascular Imaging"},{"key":"10.1016\/j.clim.2020.108397_bb0170","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis & Rheumatology (Hoboken, NJ)"},{"key":"10.1016\/j.clim.2020.108397_bb0175","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.140021","article-title":"High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease","volume":"41","author":"Haroon","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0180","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The \u2018psoriatic march\u2019: a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.clim.2020.108397_bb0185","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/rheumatology\/ket343","article-title":"Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study","volume":"53","author":"Dubreuil","year":"2014","journal-title":"Rheumatol. (Oxford, England)"},{"key":"10.1016\/j.clim.2020.108397_bb0190","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjd.12473","article-title":"Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"169","author":"Coto-Segura","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2020.108397_bb0195","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/ard.2009.125476","article-title":"Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis","volume":"69","author":"Solomon","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0200","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/exd.13393","article-title":"Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes","volume":"26","author":"Wang","year":"2017","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.clim.2020.108397_bb0205","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/met.2009.0124","article-title":"Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis","volume":"8","author":"Raychaudhuri","year":"2010","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.clim.2020.108397_bb0210","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.22185","article-title":"Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis","volume":"66","author":"Labitigan","year":"2014","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108397_bb0215","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/acr.23094","article-title":"Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study","volume":"69","author":"Jafri","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108397_bb0220","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/acr.20363","article-title":"Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108397_bb0225","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","article-title":"Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation","volume":"47","author":"Tam","year":"2008","journal-title":"Rheumatol. (Oxford, England)"},{"key":"10.1016\/j.clim.2020.108397_bb0230","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5152\/eurjrheum.2017.16052","article-title":"Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with psoriatic arthritis","volume":"4","author":"Ozkan","year":"2017","journal-title":"Eur. J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0235","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"di Minno","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108397_bb0240","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0245","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clim.2020.108397_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6070068","article-title":"Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases","volume":"6","author":"Chehimi","year":"2017","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.clim.2020.108397_bb0255","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3899\/jrheum.141112","article-title":"Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian dermatology-rheumatology comorbidity initiative","volume":"42","author":"Roubille","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0260","first-page":"1241","article-title":"Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms","volume":"27","author":"Scarpa","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0265","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.clim.2020.108397_bb0270","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn\u2019s disease in US women","volume":"72","author":"Li","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0275","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cyto.2011.08.036","article-title":"TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation","volume":"56","author":"Olsen","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.clim.2020.108397_bb0280","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/MIB.0000000000000750","article-title":"Current understanding of dysbiosis in disease in human and animal models","volume":"22","author":"DeGruttola","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0285","first-page":"1452","article-title":"The evidence for microbiome manipulation in inflammatory arthritis","volume":"56","author":"Jethwa","year":"2017","journal-title":"Rheumatol. (Oxford, England)"},{"key":"10.1016\/j.clim.2020.108397_bb0290","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1038\/ncomms7046","article-title":"Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2020.108397_bb0295","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/gut.2009.199679","article-title":"New IBD genetics: common pathways with other diseases","volume":"60","author":"Lees","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.clim.2020.108397_bb0300","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00439-007-0397-0","article-title":"Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis","volume":"122","author":"Capon","year":"2007","journal-title":"Hum. Genet."},{"key":"10.1016\/j.clim.2020.108397_bb0305","first-page":"53","article-title":"The use of fecal calprotectin in inflammatory bowel disease","volume":"13","author":"Bjarnason","year":"2017","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"key":"10.1016\/j.clim.2020.108397_bb0310","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2020.108397_bb0315","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease","volume":"29","author":"Hohenberger","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.clim.2020.108397_bb0320","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0325","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MCG.0000000000000421","article-title":"Role of non-steroidal anti-inflammatory drugs in exacerbations of inflammatory bowel disease","volume":"50","author":"Long","year":"2016","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.clim.2020.108397_bb0330","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/ard.35.4.354","article-title":"Eye inflammation in psoriatic arthritis","volume":"35","author":"Lambert","year":"1976","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0335","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaad.2010.10.032","article-title":"Ocular psoriasis","volume":"65","author":"Rehal","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2020.108397_bb0340","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/ard.2007.075754","article-title":"Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review","volume":"67","author":"Zeboulon","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0345","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10067-015-2960-8","article-title":"Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease","volume":"34","author":"Rosenbaum","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0350","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ard.59.1.67","article-title":"Characterisation of uveitis in patients with psoriatic arthritis","volume":"59","author":"Paiva","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0355","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3109\/08820538.2016.1170161","article-title":"Psoriasis and psoriatic arthritis-related uveitis: different ophthalmological manifestations and ocular inflammation features","volume":"32","author":"Abbouda","year":"2017","journal-title":"Semin. Ophthalmol."},{"key":"10.1016\/j.clim.2020.108397_bb0360","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11926-015-0536-x","article-title":"Acute anterior uveitis and spondyloarthritis: more than meets the eye","volume":"17","author":"Khan","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.clim.2020.108397_bb0365","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","article-title":"Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis","volume":"139","author":"El-Asrar","year":"2011","journal-title":"Clin. Immunol.(Orlando, Fla)"},{"key":"10.1016\/j.clim.2020.108397_bb0370","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108397_bb0375","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients","volume":"119","author":"Diaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clim.2020.108397_bb0380","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet\u2019s disease: a multicenter study","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clim.2020.108397_bb0385","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/sarh.2002.28798","article-title":"Clinical features and predictive factors in psoriatic arthritis-related uveitis","volume":"31","author":"Queiro","year":"2002","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108397_bb0390","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/sarh.2002.33470","article-title":"Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease","volume":"31","author":"Queiro","year":"2002","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108397_bb0395","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41584-018-0097-2","article-title":"The microbiome and HLA-B27-associated acute anterior uveitis","volume":"14","author":"Rosenbaum","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0400","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/BOR.0000000000000619","article-title":"The use of biologics for uveitis associated with spondyloarthritis","volume":"31","author":"Arepalli","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0405","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.semarthrit.2019.06.004","article-title":"New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review","volume":"49","author":"Rosenbaum","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108397_bb0410","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","article-title":"Targeting interleukin-23 in the treatment of noninfectious uveitis","volume":"125","author":"Pepple","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clim.2020.108397_bb0415","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.23185","article-title":"Prevalence of malignancy in psoriatic arthritis","volume":"58","author":"Rohekar","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108397_bb0420","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/art.38339","article-title":"Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden","volume":"66","author":"Hellgren","year":"2014","journal-title":"Arthritis & Rheumatology (Hoboken, NJ)"},{"key":"10.1016\/j.clim.2020.108397_bb0425","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.38385","article-title":"A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort","volume":"66","author":"Gross","year":"2014","journal-title":"Arthritis & Rheumatology (Hoboken, NJ)"},{"key":"10.1016\/j.clim.2020.108397_bb0430","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/RHU.0000000000000364","article-title":"Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis","volume":"22","author":"Hagberg","year":"2016","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0435","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s10067-016-3396-5","article-title":"Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study","volume":"35","author":"Wilton","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0440","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/rheumatology\/kew502","article-title":"Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis","volume":"56","author":"Ogdie","year":"2017","journal-title":"Rheumatol. (Oxford, England)"},{"key":"10.1016\/j.clim.2020.108397_bb0445","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","article-title":"Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study","volume":"138","author":"Ogdie","year":"2018","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.clim.2020.108397_bb0450","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/jdv.12847","article-title":"Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis","volume":"29","author":"Candia","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.clim.2020.108397_bb0455","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s10067-019-04646-7","article-title":"Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients","volume":"38","author":"Ortolan","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0460","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/ijms17020217","article-title":"Relationship between non-alcoholic fatty liver disease and psoriasis: a novel Hepato-dermal Axis?","volume":"17","author":"Mantovani","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clim.2020.108397_bb0465","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar4049","article-title":"Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-alpha blockers treatment: a prospective study","volume":"14","author":"Di Minno","year":"2012","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.clim.2020.108397_bb0470","first-page":"299","article-title":"Fatty liver and lipotoxicity","volume":"2010","author":"Trauner","year":"1801","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.clim.2020.108397_bb0475","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1365-2133.2007.08190.x","article-title":"Psoriasis patients show signs of insulin resistance","volume":"157","author":"Boehncke","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2020.108397_bb0480","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-4632.2009.04358.x","article-title":"Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis","volume":"49","author":"Karadag","year":"2010","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.clim.2020.108397_bb0485","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1468-3083.2010.03841.x","article-title":"Psoriasis and non-alcoholic fatty liver disease","volume":"25","author":"Wenk","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.clim.2020.108397_bb0490","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/exd.12162","article-title":"Leptin induces secretion of pro-inflammatory cytokines by human keratinocytes in vitro--a possible reason for increased severity of psoriasis in patients with a high body mass index","volume":"22","author":"Xue","year":"2013","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.clim.2020.108397_bb0495","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0625.2010.01210.x","article-title":"Adipokines and psoriasis","volume":"20","author":"Gerdes","year":"2011","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.clim.2020.108397_bb0500","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/qjmed\/hcg138","article-title":"Hepatocellular damage from non-steroidal anti-inflammatory drugs","volume":"96","author":"O\u2019Connor","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.clim.2020.108397_bb0505","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00044011-200626020-00001","article-title":"Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis","volume":"26","author":"Tilling","year":"2006","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.clim.2020.108397_bb0510","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0515","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/1751-2980.12184","article-title":"A review of methotrexate-associated hepatotoxicity","volume":"15","author":"Bath","year":"2014","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0520","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/ard.2009.112136","article-title":"Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis","volume":"69","author":"Sokolove","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0525","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/ard.2009.116194","article-title":"Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study","volume":"69","author":"Seitz","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0530","first-page":"357","article-title":"Screening for nonalcoholic fatty liver disease in the primary care clinic","volume":"15","author":"Pandyarajan","year":"2019","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"key":"10.1016\/j.clim.2020.108397_bb0535","first-page":"21","article-title":"Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography","volume":"8","author":"Cheng","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.clim.2020.108397_bb0540","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4254\/wjh.v7.i6.846","article-title":"Non-alcoholic fatty liver disease: the diagnosis and management","volume":"7","author":"Abd El-Kader","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.clim.2020.108397_bb0545","first-page":"5217687","article-title":"Psoriatic arthritis is an indicator of significant renal damage in patients with psoriasis: an observational and epidemiological study","volume":"2017","author":"Khan","year":"2017","journal-title":"Int. J. Inf. Secur."},{"key":"10.1016\/j.clim.2020.108397_bb0550","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1756-185X.2011.01594.x","article-title":"A comparative study of renal dysfunction in patients with inflammatory arthropathies: strong association with cardiovascular diseases and not with anti-rheumatic therapies, inflammatory markers or duration of arthritis","volume":"14","author":"Haroon","year":"2011","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0555","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1179\/acb.2006.028","article-title":"Methotrexate should not be used for patients with end-stage kidney disease","volume":"61","author":"Boey","year":"2006","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.clim.2020.108397_bb0560","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12882-017-0673-8","article-title":"Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis","volume":"18","author":"Zhang","year":"2017","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.clim.2020.108397_bb0565","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3899\/jrheum.140067","article-title":"The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts","volume":"43","author":"Haddad","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0570","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41927-019-0094-3","article-title":"Serious infections in patients with self-reported psoriatic arthritis from the psoriasis longitudinal assessment and registry (PSOLAR) treated with biologics","volume":"3","author":"Ritchlin","year":"2019","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0575","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000631","article-title":"Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population","volume":"4","author":"Gulati","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.clim.2020.108397_bb0580","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108397_bb0585","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/BOR.0000000000000388","article-title":"Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment","volume":"29","author":"Mease","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0590","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3899\/jrheum.151491","article-title":"The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study","volume":"43","author":"Brikman","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0595","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3899\/jrheum.130797","article-title":"Depression and anxiety in psoriatic disease: prevalence and associated factors","volume":"41","author":"McDonough","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0600","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/1756-185X.13553","article-title":"Systematic review of depression and anxiety in psoriatic arthritis","volume":"22","author":"Kamalaraj","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0605","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","article-title":"Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis","volume":"45","author":"Husted","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108397_bb0610","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10067-013-2477-y","article-title":"Pain threshold and intensity in rheumatic patients: correlations with the Hamilton depression rating scale","volume":"34","author":"Bagnato","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.clim.2020.108397_bb0615","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","article-title":"Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study","volume":"76","author":"Michelsen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108397_bb0620","first-page":"495","article-title":"Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis","volume":"40","author":"Zerilli","year":"2015","journal-title":"P T"},{"key":"10.1016\/j.clim.2020.108397_bb0625","doi-asserted-by":"crossref","first-page":"212570","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: evidence to date and clinical potential","volume":"8","author":"Foulkes","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.clim.2020.108397_bb0630","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/annrheumdis-2014-205212","article-title":"Psoriasis, psoriatic arthritis and risk of gout in US men and women","volume":"74","author":"Merola","year":"2015","journal-title":"Ann. Rheum. Dis."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620301741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620301741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:01:30Z","timestamp":1761494490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661620301741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":126,"alternative-id":["S1521661620301741"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2020.108397","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidities associated with psoriatic arthritis: Review and update","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2020.108397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108397"}}